GlobeNewswire: Predictive Oncology Inc. Contains the last 10 of 284 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T09:23:53ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/02/21/2833128/0/en/Predictive-Oncology-to-Participate-in-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=27203Predictive Oncology to Participate in Upcoming Investor Conferences2024-02-21T21:05:00Z<![CDATA[PITTSBURGH, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that Raymond F. Vennare, Chief Executive Officer, will participate in three upcoming investor conferences. Please see below for additional details about the events and how to request a one-on-one meeting with management.]]>https://www.globenewswire.com/news-release/2024/01/02/2802567/0/en/Predictive-Oncology-to-Participate-in-Upcoming-San-Francisco-Conferences.html?f=22&fvtc=4&fvtv=27203Predictive Oncology to Participate in Upcoming San Francisco Conferences2024-01-02T12:00:00Z<![CDATA[PITTSBURGH, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that Raymond F. Vennare, Chief Executive Officer, will present at the upcoming Biotech Showcase, in San Francisco, CA, on January 9, 2024, at 4:00 p.m. PT. Company management will also participate in the 13th Annual LifeSci Partners Corporate Access Event and BIO Partnering @ JPM Week 2024. Please see below for additional details about the events and how to request a one-on-one meeting with management.]]>https://www.globenewswire.com/news-release/2023/11/14/2779903/0/en/Predictive-Oncology-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=27203Predictive Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update2023-11-14T12:00:00Z<![CDATA[Company to host investor call and webcast today, November 14th, at 8:30am EDT Company to host investor call and webcast today, November 14th, at 8:30am EDT]]>https://www.globenewswire.com/news-release/2023/11/08/2776220/0/en/Predictive-Oncology-Completes-AI-driven-Study-of-Ovarian-Cancer-with-UPMC-Magee-Womens-Hospital.html?f=22&fvtc=4&fvtv=27203Predictive Oncology Completes AI-driven Study of Ovarian Cancer with UPMC Magee-Womens Hospital2023-11-08T13:12:27Z<![CDATA[PITTSBURGH, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announced today that it has completed a multi-year study with UPMC Magee-Womens Hospital. The objective of the study was to evaluate the use of AI to build multi-omic machine learning (ML) models and test if these models can learn associations between the datasets and ovarian cancer patient short- and long-term survival.]]>https://www.globenewswire.com/news-release/2023/11/07/2774921/0/en/Predictive-Oncology-to-Report-Third-Quarter-2023-Financial-Results-and-Host-Conference-Call-and-Webcast-on-Tuesday-November-14-2023.html?f=22&fvtc=4&fvtv=27203Predictive Oncology to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on Tuesday, November 14, 20232023-11-07T12:00:00Z<![CDATA[Management to host conference call and webcast at 8:30am EDT Management to host conference call and webcast at 8:30am EDT]]>https://www.globenewswire.com/news-release/2023/08/10/2723254/0/en/Predictive-Oncology-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=27203Predictive Oncology Reports Second Quarter 2023 Financial Results and Provides Business Update2023-08-10T21:15:00Z<![CDATA[Company to host investor call and webcast today, August 10th, at 5:30pm EDT Company to host investor call and webcast today, August 10th, at 5:30pm EDT]]>https://www.globenewswire.com/news-release/2023/08/03/2717933/0/en/Predictive-Oncology-to-Report-Second-Quarter-2023-Financial-Results-and-Host-Conference-Call-and-Webcast-on-Thursday-August-10-2023.html?f=22&fvtc=4&fvtv=27203Predictive Oncology to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on Thursday, August 10, 20232023-08-03T12:00:00Z<![CDATA[Management to host conference call and webcast at 5:30pm EDT Management to host conference call and webcast at 5:30pm EDT]]>https://www.globenewswire.com/news-release/2023/07/18/2706325/0/en/Predictive-Oncology-Announces-Relocation-of-Corporate-Headquarters-to-Pittsburgh.html?f=22&fvtc=4&fvtv=27203Predictive Oncology Announces Relocation of Corporate Headquarters to Pittsburgh2023-07-18T12:00:00Z<![CDATA[Surrounded by world renowned universities and medical centers,Predictive Oncology is part of the next generation of Pittsburgh’s innovation ecosystem]]>https://www.globenewswire.com/news-release/2023/06/27/2695220/0/en/Predictive-Oncology-Appoints-Biopharmaceutical-Finance-Veteran-Mr-Andrew-Einhorn-to-its-Business-Advisory-Board.html?f=22&fvtc=4&fvtv=27203Predictive Oncology Appoints Biopharmaceutical Finance Veteran Mr. Andrew Einhorn to its Business Advisory Board2023-06-27T12:00:00Z<![CDATA[EAGAN, Minn., June 27, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced the appointment of biopharmaceutical finance veteran Mr. Andrew Einhorn to its Business Advisory Board.]]>https://www.globenewswire.com/news-release/2023/06/20/2691001/0/en/Predictive-Oncology-Appoints-Dr-Bernard-A-Harris-Jr-to-its-Newly-Formed-Business-Advisory-Board.html?f=22&fvtc=4&fvtv=27203Predictive Oncology Appoints Dr. Bernard A. Harris, Jr. to its Newly Formed Business Advisory Board2023-06-20T12:00:00Z<![CDATA[EAGAN, Minn., June 20, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced the appointment of Dr. Bernard A. Harris, Jr. to its newly-formed Business Advisory Board (BAB).]]>